Combining Gemcitabine and Treosulfan for Melanoma Treatment
Author Information
Author(s): Corrie P G, Shaw J, Spanswick V J, Sehmbi R, Jonson A, Mayer A, Bulusu R, Hartley J A, Cree I A
Primary Institution: Oncology Centre, Addenbrooke's Hospital, Cambridge, UK
Hypothesis
Gemcitabine may affect the persistence of treosulfan-induced DNA interstrand crosslinks.
Conclusion
The study found that while no objective responses were observed, two patients with uveal melanoma had minor responses, and the recommended dose for further study is 2.5 g/m² gemcitabine combined with 5.0 g/m² treosulfan.
Supporting Evidence
- Two uveal melanoma patients had minor responses to the treatment.
- DNA damage was detected and quantified using the Comet assay.
- The recommended dose for further study is 2.5 g/m² gemcitabine combined with 5.0 g/m² treosulfan.
Takeaway
Doctors tested a new drug combination for melanoma, and while it didn't work for most patients, a couple showed some improvement.
Methodology
Patients received escalating doses of gemcitabine combined with a fixed dose of treosulfan, and DNA damage was measured using the Comet assay.
Limitations
The study had a small sample size and no objective responses were documented.
Participant Demographics
Median age was 50 years, with 81% having cutaneous melanoma and 19% uveal melanoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website